(Q37796599)

23 August 2017

Diagnosis and management of IBS. (English)

1 reference

23 August 2017

0 references

Sarah Khan

1

1 reference

PubMed ID

20890316

23 August 2017

Lin Chang

series ordinal

2

1 reference

PubMed ID

20890316

23 August 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

Nature Reviews Gastroenterology & Hepatology

23 August 2017

1 reference

23 August 2017

7

1 reference

23 August 2017

10

1 reference

23 August 2017

565-581

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2010.137

23 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

The irritable bowel syndrome: review and a graduated multicomponent treatment approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Assessment of small intestinal bacterial overgrowth in uncomplicated acute diverticulitis of the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

New treatments for irritable bowel syndrome in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

AGA technical review on irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Irritable bowel syndrome in the general population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Irritable bowel syndrome in general practice: prevalence, characteristics, and referral

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

The epidemiology of irritable bowel syndrome in a random population: prevalence, incidence, natural history and risk factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Irritable bowel syndrome in developing countries--a disorder of civilization or colonization?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Guidelines on the irritable bowel syndrome: mechanisms and practical management.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

The relationship between psychosocial parameters and outcome in irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Irritable bowel syndrome in women having diagnostic laparoscopy or hysterectomy. Relation to gynecologic features and outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

The impact of irritable bowel syndrome on health-related quality of life

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Quality of life in persons with irritable bowel syndrome: development and validation of a new measure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Clinical determinants of health-related quality of life in patients with irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Psychosocial moderators of quality of life in irritable bowel syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Predictors of patient-assessed illness severity in irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

The burden of selected digestive diseases in the United States.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Costs of irritable bowel syndrome in the UK and US.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

The impact of somatization on the use of gastrointestinal health-care resources in patients with irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Irritable bowel syndrome and surgery: a multivariable analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

New insights into the pathophysiology of irritable bowel syndrome: implications for future treatments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Post-infectious irritable bowel syndrome following water contamination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Psychometric scores and persistence of irritable bowel after infectious diarrhoea.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Postinfectious irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

The role of psychological and biological factors in postinfective gut dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? A systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Functional abdominal pain syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Towards positive diagnosis of the irritable bowel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Inflammatory Bowel Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Evaluating a bacterial hypothesis in IBS using a modification of Koch's postulates: part 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Breath tests for gastrointestinal disease: the real deal or just a lot of hot air?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Small intestinal bacterial overgrowth in patients with irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Abnormal breath testing in IBS: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Use of serum biomarkers in a diagnostic test for irritable bowel syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

The influence of older patient-physician communication on health and health-related outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Irritable bowel syndrome patients' ideal expectations and recent experiences with healthcare providers: a national survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

What patients know about irritable bowel syndrome (IBS) and what they would like to know. National Survey on Patient Educational Needs in IBS and development and validation of the Patient Educational Needs Questionnaire (PEQ).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Efficacy of oral disodium cromoglycate in patients with irritable bowel syndrome and positive skin prick tests to foods

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Increased prevalence of irritable bowel syndrome in patients with bronchial asthma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Airway responsiveness to inhaled methacholine in patients with irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

A cytologic assay for diagnosis of food hypersensitivity in patients with irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Fructose malabsorption and symptoms of irritable bowel syndrome: guidelines for effective dietary management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Comparison of digestibility and breath hydrogen gas excretion of fructo-oligosaccharide, galactosyl-sucrose, and isomalto-oligosaccharide in healthy human subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Novartis suspends tegaserod sales at FDA's request

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Loperamide treatment of the irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Psychotropic agents in functional gastrointestinal disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Effects of tricyclic antidepressants on mechanosensitive pelvic nerve afferent fibers innervating the rat colon

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Rapid response to cognitive behavior therapy predicts treatment outcome in patients with irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Predictors of treatment outcome after cognitive behavior therapy and antispasmodic treatment for patients with irritable bowel syndrome in primary care

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Prediction of outcome from cognitive-behavioral treatment of irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Prediction of treatment outcome among patients with irritable bowel syndrome treated with group cognitive therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Hypnotherapy for treatment of irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service with examination of factors influencing responsiveness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Review article: probiotics and prebiotics in irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Acupuncture for treatment of irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Acupuncture treatment in irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

A treatment trial of acupuncture in IBS patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Herbal medicines for treatment of irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

GLP-1 playing the role of a gut regulatory compound.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.137

A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease

31 March 2020

1 reference

12 December 2020

Irritable bowel syndrome, anxiety, and depression: what are the links?

1 reference

12 December 2020

Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters

1 reference

12 December 2020

Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study

1 reference

12 December 2020

Functional gut disorders and health care seeking behavior in an Italian non-patient population

1 reference

12 December 2020

An evidence-based position statement on the management of irritable bowel syndrome

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of polyethylene glycol effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation-predominant irritable bowel syndrome.

1 reference

12 December 2020

The epidemiology of irritable bowel syndrome in North America: a systematic review

1 reference

12 December 2020

Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications

1 reference

12 December 2020

Impairment in work productivity and health-related quality of life in patients with IBS.

1 reference

12 December 2020

Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome

1 reference

12 December 2020

Oral disodium cromoglycate treatment on irritable bowel syndrome: an open study on 101 subjects with diarrheic type

1 reference

12 December 2020

Symptoms across the menstrual cycle in women with irritable bowel syndrome.

1 reference

12 December 2020

10.1038/NRGASTRO.2010.137

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20890316